The FDA recently released a Drug Safety Communication announcing revisions to metformin’s label to expand use in people with type 2 diabetes and mild to moderate kidney (renal) impairment. Previously, the FDA advised against using metformin (Glucophage, Glumetza, Riomet, and Fortamet) in this group.
-
-
Recent Posts
-
-